SPARK spinout raises $64 million
Posted on April 5th, 2018
Author: Mark Terry
San Francisco-based Eidos Therapeutics closed on a $64 million Series B financing round. It was led by RA Capital Management and included Eidos’ parent company, BioBridge Pharma. It was joined by new investors Janus Henderson, Viking Global Investors, Aisling Capital, Perceptive Advisors, Cormorant Asset Management and Amzak Health Investors.
The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials. AG10 is an oral, small molecule that stabilizes tetrameric TTR. It is being evaluated to treat transthyretin amyloidosis (ATTR), a rare genetic disease.
…
The company launched in April 2017 with a $27 million commitment by BridgeBio. The company’s focus is on TTR amyloidosis. AG10 was discovered and began development by the company’s co-founders, Isabella Graef and Marmoun Alhamadsheh, via research funded by Stanford Medicine’s SPARK program. To date, the company has raised a total of $91 million.
Permalink: https://sparkmed.stanford.edu/spark-spinout-raises-64-million/